A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001471/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have contained docetaxel.
提供机构：
Vivli
创建时间：
2018-10-27
